Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Preferred Stock Liabilities (2022 - 2025)

Envoy Medical's Preferred Stock Liabilities history spans 3 years, with the latest figure at $391000.0 for Q4 2025.

  • Quarterly results put Preferred Stock Liabilities at $391000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $391000.0 (changed N/A YoY), and the annual figure for FY2025 was $391000.0, changed.
  • Preferred Stock Liabilities for Q4 2025 was $391000.0 at Envoy Medical, up from $130000.0 in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $429.7 million in Q4 2022 to a low of $130000.0 in Q3 2025.
  • The 3-year median for Preferred Stock Liabilities is $234.8 million (2022), against an average of $224.5 million.
  • Peak annual rise in Preferred Stock Liabilities hit 89.51% in 2023, while the deepest fall reached 89.61% in 2023.
  • Year by year, Preferred Stock Liabilities stood at $429.7 million in 2022, then tumbled by 89.62% to $44.6 million in 2023, then plummeted by 99.12% to $391000.0 in 2025.
  • According to Business Quant data, Preferred Stock Liabilities over the past three periods came in at $391000.0, $130000.0, and $44.6 million for Q4 2025, Q3 2025, and Q2 2023 respectively.